Article Page

Abstract

The prognosis of patients with advanced biliary tract cancer (BTC) is extremely poor and thereare only a few standard treatments. We conducted a phase I trial to investigate the safety, immune response,and antitumor effect of vaccination with four peptides derived from cancer-testis antigens, with a focus ontheir fluctuations during long-term vaccination until the disease had progressed. A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery. Bioinformatics, 25, i305–i312.]. These algorithms have been extensively benchmarked and shown to outperform most existing algorithms. Moreover, several predictions resulting from SMAP-WS have been validated experimentally. Thus far SMAP-WS has been applied to predict drug side effects, and to repurpose existing drugs for new indications. SMAP-WS provides both a user-friendly web interface and programming API for scientists to address a wide range of compute intense questions in biology and drug discovery. Here, we have for the first time discovered a multi-epitope mimic poly-pharmacophore to Multiple Peptides Derived from Cancer-Testis Antigens for the maintance of a Specific T-cell Response in Long-term Vaccinated patients with Advanced Biliary Tract Cancer using the BiogenetoligandorolTM based SMAP-WS chemical informatic parallel web service for structural proteome-wide ligand-binding site comparison.

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Algebraically in silico discovered of a multi-epitope mimic poly-pharmacophore to Multiple Peptides Derived from Cancer-Testis Antigens as a promising anti-tumor pharmaco-agent for the maintance of a Specific T-cell Response in Long-term Vaccinated patients Advanced Biliary Tract Cancer using a parallel web service for structural proteome-wide ligand-binding site comparison.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available